Applitech invites you to attend the 5th ADC Drug Development Summit (ADC2024)

As of October 30, 2023, 15 ADC drugs have been approved worldwide. Since 2018, academic and industrial efforts have yielded promising clinical benefits and significant progress. Enhertu, for example, is a breakthrough treatment for HER2 + cancer that shows great potential to be a blockbuster. The global ADC market size will grow to $7.9 billion in 2022, with a compound annual growth rate of 40.4% from 2018 to 2022. Innovative coupling platforms, optimized DAR, and improved connectors combine to improve ADC accuracy, clinical efficiency, and reduce off-target toxicity. ADC drug development in China has also successfully attracted investment, collaboration and licensing from large pharmaceutical companies worldwide. In this context, we will host the 5th ADC Drug Development Summit. We look forward to meeting you live!

ADC2024 Conference, sponsored by Touch Bio, lasted for 2 days. The conference started from 9 featured topics, focusing on "ADC drug comprehensive renaissance investment hot spots/authorized cooperation mergers and acquisitions; innovation platform to transform ADC drug design and development."(specificity/toxin/linker); broader coupling: from ADC to next-generation innovative coupling therapeutic entities; simplified clinical development: driving candidate molecules from laboratory to clinical and commercial; target screening and discovery: preclinical development/rapid antibody discovery platform; process development and quality analysis: innovative upstream and downstream processes/rapid characterization analysis & bioanalytical strategies "and other sub-fields, 60+ pharmaceutical companies and 1000+ professionals will discuss the development and future of ADC drugs.

Meeting time: March 1 - 2, 2024 (two days)

Venue: Hilton Hotel, Sunshine City, Suzhou

Conference size: 1000+ professional audience

Guiding unit: National Center for Biotechnology Innovation

Applitech Booth No.B09

Welcome colleagues in the industry to stand B09 for interaction and exquisite gifts.

Applitech Biological Technology Co., Ltd is committed to providing professional biotechnology solutions. Based on the optimization, amplification and production of biological process, we insist on improving the product line of the biopharmaceutical field for cell culture, process detection, on-line sampling, sample processing, etc. . To meet the needs of the rapid development of the biopharmaceutical industry, Applitech specializes in the development and production of single use Bioreactor, consumables and other biological process equipments. Applitech has been constantly improving the product line of the biopharmaceutical field to provide users with a full range of professional product solutions.Applitech organizes seminars and training courses every year for industry policy makers and researchers to learn and share technology achievements.

At present, Applitech has offices in Guangzhou, Beijing, Shanghai, Chengdu and other places, covering the whole country. We are adhering to the service tenet of "professional technology, considerate service and fast action", customer-oriented, working closely with technical partners to jointly escort the development of China's biopharmaceutical industry!